Bassères Eugénie, Endres Bradley T, Dotson Kierra M, Alam M Jahangir, Garey Kevin W
University of Houston College of Pharmacy, Houston, Texas, USA.
Curr Opin Gastroenterol. 2017 Jan;33(1):1-7. doi: 10.1097/MOG.0000000000000332.
Clostridium difficile infections (CDI) remain a challenge to treat clinically due primarily to limited number of antibiotics available and unacceptably high recurrence rates. Because of this, there has been significant demand for creating innovative therapeutics, which has resulted in the development of several novel antibiotics.
This review updates seven different antibiotics that are currently in development to treat CDI including fidaxomicin, surotomycin, ridinilazole, ramoplanin, cadazolid, LFF571, and CRS3123. Available preclinical and clinical data are compared between these antibiotics.
Many of these new antibiotics display almost ideal properties for antibiotics directed against CDI. Despite these properties, not all clinical development of these compounds has been successful. These studies have provided key insights into the pathogenesis of CDI and will continue to inform future drug development. Successful phase III clinical trials should result in several new and novel antibiotics to treat CDI.
艰难梭菌感染（CDI）在临床上的治疗仍然是一项挑战，主要原因是可用抗生素数量有限且复发率高得令人难以接受。因此，人们对创新疗法有巨大需求，这导致了几种新型抗生素的研发。
本综述更新了目前正在研发用于治疗CDI的七种不同抗生素，包括非达霉素、苏罗霉素、利地那唑、雷莫拉宁、卡达唑胺、LFF571和CRS3123。对这些抗生素之间可用的临床前和临床数据进行了比较。
这些新型抗生素中的许多都展现出针对CDI的抗生素几乎理想的特性。尽管有这些特性，但并非所有这些化合物的临床开发都取得了成功。这些研究为CDI的发病机制提供了关键见解，并将继续为未来的药物开发提供信息。成功的III期临床试验应能带来几种治疗CDI的新型抗生素。
